Hepatitis
Cohort Study: Among patients with resolved Hepatitis B infections and concomitant autoimmune disease, exposure to prednisone doses greater than 20 mg/day were associated with a high risk for HBV reactivation or hepatitis flare.
21 Jan, 2022 | 09:39h | UTCAverage corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection – Annals of Rheumatic Disease (link to abstract – $ for full-text)
Commentary on Twitter
Patients with time-weighted average prednisone dose greater than 20 mg/day would be classified as the high risk for HBV reactivation or hepatitis flare. Prophylactic Anti-HBV therapy may be needed for these high-risk patientshttps://t.co/qLuirdyXDK pic.twitter.com/yDJ4c072qm
— ARD & RMD Open (@ARD_BMJ) December 23, 2021
WHO Urges Countries to Increase Hepatitis Services.
3 Aug, 2021 | 02:26h | UTCWHO Urges Countries to Increase Hepatitis Services – Health Policy Watch
WHO Campaign: World Hepatitis Day (28 July)
New WHO guidelines:
Recommendations and guidance on hepatitis C virus self-testing – World Health Organization
Interim guidance for country validation of viral hepatitis elimination – World Health Organization
WHO releases first-ever global guidance for country validation of viral hepatitis B and C elimination.
15 Jul, 2021 | 09:16h | UTCSee guidance: Interim guidance for country validation of viral hepatitis elimination – World Health Organization
New WHO report highlights global progress on reducing HIV, viral hepatitis and sexually transmitted infections and signals need for renewed efforts to reach 2030 targets.
21 May, 2021 | 08:33h | UTCOriginal report: Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 – World Health Organization
Commentary on Twitter (thread – click for more)
Every year HIV, viral hepatitis, and sexually transmitted infections account for 2.3M deaths, and 1.2M cancers
🆕WHO report highlights achievements, gaps, and actions towards eliminating these diseases as public health threats by 2030 👉https://t.co/8kcVqZe0Yj pic.twitter.com/U07hKRumVt
— World Health Organization (WHO) (@WHO) May 20, 2021
Recommendations on the Management of Maternal Hepatitis B, C and D Infection in Pregnancy
25 Apr, 2021 | 20:44h | UTC
RCT: Ravidasvir plus sofosbuvir are effective and well tolerated in patients with chronic HCV infection, with potential as an affordable treatment for these patients
18 Apr, 2021 | 21:19h | UTC
Commentary on Twitter
Trial results of new affordable #hepatitisC treatment showing 97% cure rate now published in @LancetGastroHep!
Ravidasvir + sofosbuvir has the potential to provide an additional affordable, simple, and efficacious #publichealth tool to eliminate HCV.
➡️https://t.co/Oo1ZHQnyn6 pic.twitter.com/FcFntfYMSC
— Drugs for Neglected Diseases initiative (@DNDi) April 16, 2021
USPSTF recommends screening for Hepatitis B Virus infection in adolescents and adults
13 Jan, 2021 | 01:43h | UTCAuthor Interview: USPSTF Recommendation: Screening for Hepatitis B Virus Infection in Adolescents and Adults
Patient Page: Screening for Hepatitis B in Nonpregnant Adolescents and Adults – JAMA